GNPX News and Press, Genprex Inc. From 02/23/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Postmodern Studio / Shutterstock.com Teladoc (NYSE: TDOC ) stock is on the move Thursday after getting an upgrade from SVB Securities . That upgrade has SVB Securities analysts boosting TDOC stock from a ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Connect world / Shutterstock.com Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment . That positive news comes from a trial of gene therap...

Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 Genprex Announces Groundbreaking Data from Non-Human Primate Study...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into an exclusive license agreement with the University of Pittsburgh. According to the announcement, the agreement gives Genprex a world...

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh PR Newswire Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Million...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that research evaluating the company’s gene therapy for type 1 diabetes will be presented at the 16th International Conference on Ad...

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies &...

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh PR Newswire Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN , Texas , Dec. 15, 2022 /PRNewswire/ --...

Genprex ( NASDAQ: GNPX ) said a Safety Review Committee (SRC) approved continuation to the third and final group in the dose escalation phase 1 part of a phase 1/2 trial. The study, dubbed Acclaim-1, is evaluating Reqorsa in combination with  in combination with AstraZen...

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Recommendation to Advance to Increased Dose in Third a...